{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T17:25:04Z","timestamp":1787246704758,"version":"build-2736575974"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s13555-026-01811-0","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T06:22:34Z","timestamp":1782973354000},"page":"3831-3845","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Rituximab in Pemphigus Foliaceus: A Systematic Review and Meta-analysis"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-6819-6662","authenticated-orcid":false,"given":"Camille","family":"Kieffer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivien","family":"Hebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Billal","family":"Tedbirt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"issue":"2","key":"1811_CR1","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s12026-018-8986-7","volume":"66","author":"K Kridin","year":"2018","unstructured":"Kridin K. Pemphigus group: overview, epidemiology, mortality, and comorbidities. Immunol Res. 2018;66(2):255\u201370. https:\/\/doi.org\/10.1007\/s12026-018-8986-7.","journal-title":"Immunol Res"},{"issue":"2","key":"1811_CR2","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.jid.2018.07.042","volume":"139","author":"L Jelti","year":"2019","unstructured":"Jelti L, Cordel N, Gillibert A, et al. Incidence and mortality of pemphigus in France. J Invest Dermatol. 2019;139(2):469\u201373. https:\/\/doi.org\/10.1016\/j.jid.2018.07.042.","journal-title":"J Invest Dermatol"},{"issue":"12","key":"1811_CR3","first-page":"874","volume":"120","author":"L Dehen","year":"1993","unstructured":"Dehen L, Crickx B, Grossin M, Bela\u00efch S. [Comparative study of the development and prognosis of Pemphigus vulgaris and seborrheic pemphigus]. Ann Dermatol Venereol. 1993;120(12):874\u20138.","journal-title":"Ann Dermatol Venereol"},{"issue":"4","key":"1811_CR4","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.jaad.2013.05.016","volume":"69","author":"N Almugairen","year":"2013","unstructured":"Almugairen N, Hospital V, Bedane C, et al. Assessment of the rate of long-term complete remission off therapy in patients with pemphigus treated with different regimens including medium- and high-dose corticosteroids. J Am Acad Dermatol. 2013;69(4):583\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2013.05.016.","journal-title":"J Am Acad Dermatol"},{"issue":"10083","key":"1811_CR5","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","volume":"389","author":"P Joly","year":"2017","unstructured":"Joly P, Maho-Vaillant M, Prost-Squarcioni C, et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux\u00a03): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017;389(10083):2031\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(17)30070-3.","journal-title":"Lancet"},{"issue":"9","key":"1811_CR6","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1111\/jdv.16752","volume":"34","author":"P Joly","year":"2020","unstructured":"Joly P, Horvath B, Patsatsi \u0391, et al. Updated S2K guidelines on the management of Pemphigus vulgaris and foliaceus initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2020;34(9):1900\u201313. https:\/\/doi.org\/10.1111\/jdv.16752.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1811_CR7","unstructured":"PROSPERO. https:\/\/www.crd.york.ac.uk\/prospero\/. Accessed May 2025."},{"key":"1811_CR8","unstructured":"PRISMA. http:\/\/www.prisma-statement.org\/?AspxAutoDetectCookieSupport=1. Accessed May 2025."},{"key":"1811_CR9","doi-asserted-by":"crossref","unstructured":"Rayyan. https:\/\/www.rayyan.ai\/. Accessed May 2025.","DOI":"10.5339\/jist.2025.15"},{"issue":"6","key":"1811_CR10","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.jaad.2008.01.012","volume":"58","author":"DF Murrell","year":"2008","unstructured":"Murrell DF, Dick S, Ahmed AR, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol. 2008;58(6):1043\u20136. https:\/\/doi.org\/10.1016\/j.jaad.2008.01.012.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1811_CR11","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1080\/02763869.2013.837734","volume":"32","author":"E Vardell","year":"2013","unstructured":"Vardell E, Malloy M. Joanna Briggs Institute: an evidence-based practice database. Med Ref Serv Q. 2013;32(4):434\u201342. https:\/\/doi.org\/10.1080\/02763869.2013.837734.","journal-title":"Med Ref Serv Q"},{"issue":"9","key":"1811_CR12","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","volume":"73","author":"K Slim","year":"2003","unstructured":"Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (MINORS): development and validation of a new instrument. ANZ J Surg. 2003;73(9):712\u20136. https:\/\/doi.org\/10.1046\/j.1445-2197.2003.02748.x.","journal-title":"ANZ J Surg"},{"issue":"2","key":"1811_CR13","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/jdv.12080","volume":"28","author":"HH Cho","year":"2014","unstructured":"Cho HH, Jin S-P, Chung JH. Clinical experiences of different dosing schedules of rituximab in pemphigus with various disease severities. J Eur Acad Dermatol Venereol. 2014;28(2):186\u201391. https:\/\/doi.org\/10.1111\/jdv.12080.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1811_CR14","doi-asserted-by":"publisher","first-page":"472","DOI":"10.2340\/00015555-1746","volume":"94","author":"Y Cho","year":"2014","unstructured":"Cho Y, Lee F, Chu C, Wang L. First-line combination therapy with rituximab and corticosteroids is effective and safe for pemphigus. Acta Derm Venereol. 2014;94(4):472\u20133. https:\/\/doi.org\/10.2340\/00015555-1746.","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"1811_CR15","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1111\/bjd.13586","volume":"172","author":"L De Sena Nogueira Maehara","year":"2015","unstructured":"De Sena Nogueira Maehara L, Huizinga J, Jonkman MF. Rituximab therapy in pemphigus foliaceus: report of 12 cases and review of recent literature. Br J Dermatol. 2015;172(5):1420\u20133. https:\/\/doi.org\/10.1111\/bjd.13586.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1811_CR16","doi-asserted-by":"publisher","first-page":"317","DOI":"10.4103\/ijdvl.IJDVL_1078_14","volume":"83","author":"J Gupta","year":"2017","unstructured":"Gupta J, Raval R, Shah A, et al. Low-dose rituximab as an adjuvant therapy in pemphigus. Indian J Dermatol Venereol Leprol. 2017;83(3):317. https:\/\/doi.org\/10.4103\/ijdvl.IJDVL_1078_14.","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"2","key":"1811_CR17","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1080\/09546634.2018.1484873","volume":"30","author":"I Hamadah","year":"2019","unstructured":"Hamadah I, Chisti MA, Haider M, et al. Rituximab\/IVIG in pemphigus \u2013 a 10-year study with a long follow-up. J Dermatol Treat. 2019;30(2):170\u20135. https:\/\/doi.org\/10.1080\/09546634.2018.1484873.","journal-title":"J Dermatol Treat"},{"issue":"2","key":"1811_CR18","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/j.1365-2133.2011.10663.x","volume":"166","author":"B Horv\u00e1th","year":"2012","unstructured":"Horv\u00e1th B, Huizinga J, Pas HH, Mulder AB, Jonkman MF. Low-dose rituximab is effective in pemphigus: low-dose rituximab in pemphigus. Br J Dermatol. 2012;166(2):405\u201312. https:\/\/doi.org\/10.1111\/j.1365-2133.2011.10663.x.","journal-title":"Br J Dermatol"},{"key":"1811_CR19","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.2147\/DDDT.S306046","volume":"15","author":"S Kanokrungsee","year":"2021","unstructured":"Kanokrungsee S, Anuntrangsee T, Tankunakorn J, Srisuwanwattana P, Suchonwanit P, Chanprapaph K. rituximab therapy for treatment of pemphigus in Southeast Asians. Drug Des Devel Ther. 2021;15:1677\u201390. https:\/\/doi.org\/10.2147\/DDDT.S306046.","journal-title":"Drug Des Devel Ther"},{"issue":"6","key":"1811_CR20","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/bjd.12972","volume":"170","author":"AJ Kanwar","year":"2014","unstructured":"Kanwar AJ, Vinay K, Sawatkar GU, et al. Clinical and immunological outcomes of high- and low-dose rituximab treatments in patients with pemphigus: a randomized, comparative, observer-blinded study. Br J Dermatol. 2014;170(6):6. https:\/\/doi.org\/10.1111\/bjd.12972.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1811_CR21","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/j.1365-2133.2011.10585.x","volume":"166","author":"M Kasperkiewicz","year":"2012","unstructured":"Kasperkiewicz M, Shimanovich I, Meier M, et al. Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine\/mycophenolate mofetil: a pilot study of 23 patients. Br J Dermatol. 2012;166(1):154\u201360. https:\/\/doi.org\/10.1111\/j.1365-2133.2011.10585.x.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1811_CR22","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/1346-8138.14732","volume":"46","author":"Y Kurihara","year":"2019","unstructured":"Kurihara Y, Yamagami J, Funakoshi T, et al. Rituximab therapy for refractory autoimmune bullous diseases: a multicenter, open-label, single-arm, phase\u00a01\/2 study on 10 Japanese patients. J Dermatol. 2019;46(2):124\u201330. https:\/\/doi.org\/10.1111\/1346-8138.14732.","journal-title":"J Dermatol"},{"key":"1811_CR23","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2012.1522","author":"L Lunardon","year":"2012","unstructured":"Lunardon L, Tsai KJ, Propert KJ, et al. Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients. Arch Dermatol. 2012. https:\/\/doi.org\/10.1001\/archdermatol.2012.1522.","journal-title":"Arch Dermatol"},{"issue":"3","key":"1811_CR24","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1080\/09546634.2020.1836309","volume":"33","author":"A Nili","year":"2022","unstructured":"Nili A, Mahmoudi H, Heidari N, et al. Rituximab monotherapy in mild pemphigus. J Dermatol Treat. 2022;33(3):1784\u20136. https:\/\/doi.org\/10.1080\/09546634.2020.1836309.","journal-title":"J Dermatol Treat"},{"issue":"2","key":"1811_CR25","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.jaad.2018.05.1252","volume":"85","author":"I Palacios-\u00c1lvarez","year":"2021","unstructured":"Palacios-\u00c1lvarez I, Riquelme-Mc Loughlin C, Curto-Barredo L, Iranzo P, Garc\u00eda-D\u00edez I, Espa\u00f1a A. Rituximab treatment of pemphigus foliaceus: a retrospective study of 12 patients. J Am Acad Dermatol. 2021;85(2):484\u20136. https:\/\/doi.org\/10.1016\/j.jaad.2018.05.1252.","journal-title":"J Am Acad Dermatol"},{"key":"1811_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.metop.2021.100142","volume":"12","author":"V Perifani","year":"2021","unstructured":"Perifani V, Dalamaga M, Theodoropoulos K, et al. Real world evidence: patients with refractory pemphigus treated with rituximab. Metabolism Open. 2021;12:100142. https:\/\/doi.org\/10.1016\/j.metop.2021.100142.","journal-title":"Metabolism Open"},{"issue":"5","key":"1811_CR27","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/j.jaad.2020.06.024","volume":"83","author":"H Rashid","year":"2020","unstructured":"Rashid H, Lamberts A, Van Maanen D, et al. The effectiveness of rituximab in pemphigus and the benefit of additional maintenance infusions: daily practice data from a retrospective study. J Am Acad Dermatol. 2020;83(5):1503\u20135. https:\/\/doi.org\/10.1016\/j.jaad.2020.06.024.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1811_CR28","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.jaad.2011.12.019","volume":"67","author":"Z Reguiai","year":"2012","unstructured":"Reguiai Z, Tabary T, Maizi\u00e8res M, Bernard P. Rituximab treatment of severe pemphigus: long-term results including immunologic follow-up. J Am Acad Dermatol. 2012;67(4):623\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2011.12.019.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1811_CR29","first-page":"47","volume":"13","author":"J Sakhiya","year":"2020","unstructured":"Sakhiya J, Sakhiya D, Khambhati R, et al. Modified rheumatoid arthritis protocol for rituximab in pemphigus: a retrospective case series. J Clin Aesthetic Dermatol. 2020;13(2):47\u201352.","journal-title":"J Clin Aesthetic Dermatol"},{"issue":"1","key":"1811_CR30","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jaad.2018.01.029","volume":"79","author":"MA Saleh","year":"2018","unstructured":"Saleh MA. A prospective study comparing patients with early and late relapsing pemphigus treated with rituximab. J Am Acad Dermatol. 2018;79(1):97\u2013103. https:\/\/doi.org\/10.1016\/j.jaad.2018.01.029.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1811_CR31","doi-asserted-by":"publisher","first-page":"389","DOI":"10.4103\/0378-6323.174379","volume":"82","author":"V Sharma","year":"2016","unstructured":"Sharma V, Bhari N, Gupta S, et al. Clinical efficacy of rituximab in the treatment of pemphigus: a retrospective study. Indian J Dermatol Venereol Leprol. 2016;82(4):389. https:\/\/doi.org\/10.4103\/0378-6323.174379.","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"12","key":"1811_CR32","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/jdv.16561","volume":"34","author":"I Shimanovich","year":"2020","unstructured":"Shimanovich I, Baumann T, Schmidt E, Zillikens D, Hammers CM. Long-term outcomes of rituximab therapy in pemphigus. J Eur Acad Dermatol Venereol. 2020;34(12):12. https:\/\/doi.org\/10.1111\/jdv.16561.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1811_CR33","doi-asserted-by":"publisher","first-page":"642","DOI":"10.18203\/issn.2455-4529.IntJResDermatol20213174","volume":"7","author":"SK Singh","year":"2021","unstructured":"Singh SK, Satyaraj P, Sachan P. A prospective observational study on efficacy of modified rheumatoid arthritis protocol of rituximab (2000\u00a0mg) on patients of pemphigus. Int J Res Dermatol. 2021;7(5):642. https:\/\/doi.org\/10.18203\/issn.2455-4529.IntJResDermatol20213174.","journal-title":"Int J Res Dermatol"},{"issue":"4","key":"1811_CR34","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1001\/jamadermatol.2024.6654","volume":"161","author":"B Tedbirt","year":"2025","unstructured":"Tedbirt B, Houivet E, Maho-Vaillant M, et al. Long-term efficacy and safety of rituximab in patients with pemphigus foliaceus compared with pemphigus vulgaris. JAMA Dermatol. 2025;161(4):444. https:\/\/doi.org\/10.1001\/jamadermatol.2024.6654.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"1811_CR35","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1111\/bjd.13307","volume":"172","author":"D Tomsitz","year":"2015","unstructured":"Tomsitz D, Stefaniak R, Worm M. Rituximab in patients with recalcitrant autoimmune blistering diseases: experience in a cohort of 22 patients. Br J Dermatol. 2015;172(3):829\u201331. https:\/\/doi.org\/10.1111\/bjd.13307.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1811_CR36","doi-asserted-by":"publisher","first-page":"477","DOI":"10.4103\/ijd.ijd_169_22","volume":"67","author":"G Verma","year":"2022","unstructured":"Verma G, Sharma A, Rattan R, Negi A, Gupta M, Sharma R. Experience of rituximab therapy in pemphigus: a three-year retrospective study from a sub-Himalayan state. Indian J Dermatol. 2022;67(4):477. https:\/\/doi.org\/10.4103\/ijd.ijd_169_22.","journal-title":"Indian J Dermatol"},{"issue":"4","key":"1811_CR37","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1093\/bjd\/ljaf190","volume":"193","author":"S Tzoumpa","year":"2025","unstructured":"Tzoumpa S, Bohelay G, Ingen-Housz-Oro S, et al. Evaluation of the efficacy and safety of dapsone alone or associated with topical corticosteroids for pemphigus foliaceus: a retrospective multicentre study. Br J Dermatol. 2025;193(4):773\u20135. https:\/\/doi.org\/10.1093\/bjd\/ljaf190.","journal-title":"Br J Dermatol"},{"issue":"24","key":"1811_CR38","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa2028564","volume":"384","author":"VP Werth","year":"2021","unstructured":"Werth VP, Joly P, Mimouni D, et al. Rituximab versus mycophenolate mofetil in patients with pemphigus vulgaris. N Engl J Med. 2021;384(24):2295\u2013305. https:\/\/doi.org\/10.1056\/NEJMoa2028564.","journal-title":"N Engl J Med"},{"issue":"3","key":"1811_CR39","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1001\/jamadermatol.2023.5679","volume":"160","author":"B Tedbirt","year":"2024","unstructured":"Tedbirt B, Maho-Vaillant M, Houivet E, et al. Sustained remission without corticosteroids among patients with pemphigus who had rituximab as first-line therapy: follow-up of the ritux 3 trial. JAMA Dermatol. 2024;160(3):290. https:\/\/doi.org\/10.1001\/jamadermatol.2023.5679.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"1811_CR40","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/bjd\/ljaf152","volume":"193","author":"MAJ Hiel","year":"2025","unstructured":"Hiel MAJ, Korte EWH, Tedbirt B, et al. Outcome measurement in pemphigus clinical research: a scoping review on heterogeneity in outcome reporting and definitions. Br J Dermatol. 2025;193(2):221\u201331. https:\/\/doi.org\/10.1093\/bjd\/ljaf152.","journal-title":"Br J Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01811-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01811-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01811-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:30:12Z","timestamp":1787243412000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01811-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1811"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01811-0","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"assertion":[{"value":"22 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Pascal Joly is consultant for Amgen, Argenx, AstraZeneca, Thermo Fisher, Sanofi, Akari, Janssen, Novartis, Servier, Chugai, Kezar Life Science, Regeneron, UCB, Principabio, Zenyaku Kogyo, Dualyx, JJP Biologics. Vivien H\u00e9bert is consultant for AstraZeneca, Pfizer, Almirall, UCB, Lilly, Abbvie, BMS. Camille Kieffer and Billal Tedbirt declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}